Literature DB >> 9134374

Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal control subjects.

I C Steele1, G McDowell, A Moore, N P Campbell, C Shaw, K D Buchanan, D P Nicholls.   

Abstract

Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are known to be elevated in patients with chronic heart failure at rest. While it is known that during exercise the circulating level of ANP increases in patients with heart failure, the response of BNP to exercise in these patients relative to control subjects is unclear. Ten patients with stable chronic heart failure and 10 normal control subjects performed symptom-limited exercise with respired gas analysis. All patients had depressed left ventricular ejection fractions (LVEF). Patients had lower peak oxygen consumption PVo2) than the control group [median (range) 1.18 (0.98-1.76) vs. 1.94 (1.53-2.31) L min-1; P < 0.001]. Circulating plasma levels of ANP and BNP were higher at rest in patients than in control subjects [ANP 335 (140-700) vs. 90 (25-500) pg mL-1; BNP 42 (25-50) vs. 20 (10-20) pg mL-1], and at peak exercise [ANP 400 (200-1000) vs. 130 (10-590); BNP 46 (40-51) vs. 20 (10-30)]. The rise in ANP at peak exercise was significant in patients compared with the resting level, but not in control subjects. For BNP, there was a significant rise in patients but no change in control subjects. The circulating plasma levels of both peptides showed a strong negative correlation with LVEF (ANP, P < 0.005; BNP, P < 0.0001) and, to a less extent, with RVEF. It is possible that BNP may give a better indication of cardiac function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9134374     DOI: 10.1046/j.1365-2362.1997.1070653.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  The role of brain natriuretic peptide in the prediction of cardiac performance in coronary artery bypass grafting.

Authors:  Osman Saribulbul; Ilker Alat; Senol Coskun; Anil Z Apaydin; Tahir Yagdi; Mefkure Kiliccioglu; Emin Alp Alayunt
Journal:  Tex Heart Inst J       Date:  2003

2.  Influence of acute and chronic myocardial loading conditions, function, structural changes and extracardiac factors on NT-proBNP in asymptomatic patients with preserved ejection fraction.

Authors:  Olaf Schulz; Andre Rudolph; Sarah Scheiner; Helena Mut; Jeanette Schulz-Menger; Gunnar Berghoefer; Ricarda Bensch; Jochen Kraemer; Ingolf Schimke
Journal:  Clin Res Cardiol       Date:  2010-09-02       Impact factor: 5.460

3.  Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study.

Authors:  Raquel Cortés; Miguel Rivera; Antonio Salvador; Vicente Bertomeu; Fernando García de Burgos; Esther Roselló-Lletí; Manuel Portolés; Rafael Payá; Luis Martínez-Dolz; Vicente Climent
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

Review 4.  Can biomarkers help to diagnose early heart failure with preserved ejection fraction?

Authors:  Jaroslav Meluzín; Josef Tomandl
Journal:  Dis Markers       Date:  2015-01-31       Impact factor: 3.434

5.  The alteration of NTproCNP plasma levels following anaerobic exercise in physically active young men.

Authors:  Hilal Akseki Temür; Selma Arzu Vardar; Muzaffer Demir; Orkide Palabıyık; Aziz Karaca; Zuhal Guksu; Arif Ortanca; Necdet Süt
Journal:  Anatol J Cardiol       Date:  2014-04-08       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.